- Previous Close
14.62 - Open
14.20 - Bid 10.34 x 100
- Ask 17.40 x 200
- Day's Range
13.48 - 14.28 - 52 Week Range
13.48 - 25.50 - Volume
19,107 - Avg. Volume
42,973 - Market Cap (intraday)
774.449M - Beta (5Y Monthly) -2.84
- PE Ratio (TTM)
-- - EPS (TTM)
-2.84 - Earnings Date Apr 8, 2025 - Apr 23, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
37.20
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
pharvaris.comRecent News: PHVS
View More
Performance Overview: PHVS
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHVS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHVS
View MoreValuation Measures
Market Cap
770.11M
Enterprise Value
433.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.38
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.10%
Return on Equity (ttm)
-58.77%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-132.21M
Diluted EPS (ttm)
-2.84
Balance Sheet and Cash Flow
Total Cash (mrq)
305.19M
Total Debt/Equity (mrq)
0.04%
Levered Free Cash Flow (ttm)
-62.72M